Genitourinary Cancers

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Nancy B. Davis, MD, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.

Kathryn E. Beckermann, MD, PhD, discusses the available single-agent and combination options for the treatment of patients with metastatic renal cell carcinoma.

Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that oncologists can keep pace with changes associated with the agency’s accelerated approval program.

Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.

As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma.

Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.

Thai H. Ho, MD, PhD, discusses frontline treatment considerations in metastatic renal cell carcinoma, the utility of TKI monotherapy, and new combinations on the horizon.

Eric Jonasch, MD, discusses how to modulate the tumor microenvironment in renal cell carcinoma.

Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.

David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.

Three game-changing immunotherapy trials have transformed the treatment paradigm in frontline clear cell renal cell carcinoma. At the 37th Annual CFS®, Robert J. Motzer, MD, compared the findings from the three studies.

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

The European Commission has approved the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.

Enrique Grande, MD, discusses the design of the phase III IMvigor130 trial, which compared atezolizumab plus chemotherapy versus atezolizumab monotherapy (arm B) versus standard chemotherapy plus placebo in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Shilpa Gupta, MD, discusses the challenges of identifying predictive biomarkers in bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.